Arikayce liposomal
What Arikayce liposomal is used for
Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Arikayce liposomal
- Active substance
- amikacin
- Disease area
- Respiratory Tract Infections
- Medicine group
- Antibacterials for systemic use
- ATC code
- J01GB06
- Marketing authorisation holder
- Insmed Netherlands B.V.
- Authorised in the EU since
- 2020
Official information
In India
- Amikacin sulfate: 1,744 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Arikayce liposomal used for?
Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.
What is the active substance in Arikayce liposomal?
Arikayce liposomal contains amikacin.
Who makes Arikayce liposomal?
The EU marketing authorisation holder is Insmed Netherlands B.V..
Is Arikayce liposomal an orphan medicine?
Yes. Arikayce liposomal is designated an orphan medicine in the EU, for a rare disease (Respiratory Tract Infections).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU